Neurogene Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Neurogene Inc. (NGNE) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $9.84 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-11
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $9.43, a 11.95% decline year-over-year.
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $10.71, a 36.59% decline year-over-year.
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $16.89.
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $12.70, a 29.83% decline from fiscal 2024.
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $18.10, a 119.66% increase from fiscal 2023.
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $8.24, a 124.52% increase from fiscal 2022.
- Neurogene Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $3.67, a 11.89% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.84 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $9.43 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $12.70 10-K · filed 2026-03-24 | |||
| 2025-09-30 | $11.62 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $9.47 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | $10.71 10-Q · filed 2025-05-09 | |||
| 2024-12-31 | $18.10 10-K · filed 2025-03-24 | |||
| 2024-09-30 | $17.63 10-Q · filed 2024-11-18 | |||
| 2024-06-30 | $16.87 10-Q · filed 2024-08-09 | |||
| 2024-03-31 | $16.89 10-Q · filed 2024-05-10 | |||
| 2023-12-31 | $8.24 10-K · filed 2024-03-18 | |||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $3.67 10-K · filed 2023-03-20 | |||
| 2022-09-30 | $3.67 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $3.67 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $3.67 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $3.28 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $3.28 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $3.21 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $3.07 10-Q · filed 2021-05-12 | |||
| 2020-12-31 | $6.42 10-K · filed 2021-03-25 | |||
| 2020-09-30 | $7.88 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | $7.79 10-Q · filed 2020-08-12 | |||
| 2020-03-31 | $9.03 10-Q · filed 2020-05-06 | |||
| 2019-12-31 | $4.77 10-K · filed 2020-03-12 | |||
| 2019-09-30 | $3.07 10-Q · filed 2019-11-13 | |||
| 2018-12-31 | $9.28 10-K · filed 2019-03-07 | |||
| 2018-09-30 | $9.28 10-Q · filed 2018-11-07 | |||
| 2018-06-30 | $9.28 10-Q · filed 2018-08-08 | |||
| 2018-03-31 | $10.30 10-Q · filed 2018-05-08 | |||
| 2017-12-31 | $9.10 10-K · filed 2018-03-12 | |||
| 2017-09-30 | $9.35 10-Q · filed 2017-11-08 | |||
| 2017-06-30 | $9.33 10-Q · filed 2017-08-08 | |||
| 2016-12-31 | $7.91 10-K · filed 2017-03-09 | |||
| 2016-09-30 | $7.91 10-Q · filed 2016-11-09 | |||
| 2016-06-30 | $5.76 10-Q · filed 2016-08-04 | |||
| 2015-12-31 | $5.99 10-K · filed 2016-03-14 | |||
| 2015-09-30 | $5.99 10-Q · filed 2015-11-10 | |||
| 2015-06-30 | $2.98 10-Q · filed 2015-08-06 | |||
| 2015-03-31 | $2.57 10-Q · filed 2015-05-12 | |||
| 2014-12-31 | $5.76 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |